Placenta-derived gp96 as a multivalent prophylactic cancer vaccine

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Zhao, Bao ^a   Wang, Yanzhong ^a   Wu, Bo ^a   Liu, Shan ^a   Wu, Erjie ^b   Fan, Hong Xia ^b   Gui, Ming Ming ^b   Chen, Lizhao ^b   Li, Changfei ^c   Ju, Ying ^c   Zhang, Wei ^c   Meng, Songdong ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; SARCOMA GLYCOPROTEIN GP96 REJECTION ANTIGENS; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL; ARTICLE; DENDRITIC CELL; DISEASE MODEL; FEMALE; HUMAN; IMMUNOLOGY; METABOLISM; MORTALITY; MOUSE; NEOPLASM; PATHOLOGY; PLACENTA; PREGNANCY; PROTEIN BINDING; RAT; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE; TUMOR VOLUME;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; NEOPLASMS; PLACENTA; PREGNANCY; PROTEIN BINDING; RATS; T-LYMPHOCYTE SUBSETS; TUMOR BURDEN;

EID: 84899965895     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01947     Document Type: Article

References (29)

1. O'Callaghan, T. Introduction: The prevention agenda. Nature 471, S2-4 (2011)
2. Liu, M. A. Cancer vaccines. Philos Trans R Soc Lond B Biol Sci 366, 2823-2826 (2011)
3. Tuohy, V. K. &Jaini, R. Prophylactic cancer vaccination by targeting functional non-self. Ann Med 43, 356-365 (2011)
4. Pere, H. et al. A CCR4 antagonist combined with vaccines induces antigenspecific CD8(1) T cells and tumor immunity against self antigens. Blood 118, 4853-4862 (2011)
5. Nanni, P. et al. Antimetastatic activity of a preventive cancer vaccine. Cancer Res 67, 11037-11044 (2007)
6. Jaini, R. et al. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med 16, 799-803 (2010)
7. Brewer, B. G., Mitchell, R. A., Harandi, A. &Eaton, J. W. Embryonic vaccines against cancer: An early history. Exp Mol Pathol 86, 192-197 (2009)
8. Dong, W. et al. Administration of embryonic stem cells generates effective antitumor immunity in mice with minor and heavy tumor load. Cancer Immunol Immun 59, 1697-1705 (2010)
9. Yaddanapudi, K. et al. Vaccination with Embryonic Stem Cells Protects against Lung Cancer: Is a Broad-Spectrum Prophylactic Vaccine against Cancer Possible? PloS one 7, e42289 (2012)
10. Garcia-Hernandez Mde, L., Gray, A., Hubby, B., Klinger, O. J. &Kast, W. M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 68, 861-869 (2008)
11. Sood, R., Zehnder, J. L., Druzin, M. L. &Brown, P. O. Gene expression patterns in human placenta. P Natl Acad Sci USA 103, 5478-5483 (2006)
12. Robert, J., Ramanayake, T., Maniero, G. D., Morales, H. &Chida, A. S. Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation. J Immunol 180, 3176-3182 (2008)
13. Kropp, L. E., Garg, M. &Binder, R. J. Ovalbumin-derived precursor peptides are transferred sequentially from gp96 and calreticulin to MHC class I in the endoplasmic reticulum. J Immunol 184, 5619-5627 (2010)
14. Meng, S. D., Gao, T., Gao, G. F. &Tien, P. HBV-specific peptide associated with heat-shock protein gp96. Lancet 357, 528-529 (2001)
15. Liu, Z. et al. Treg suppress CTL responses upon immunization with HSP gp96. Eur J Immunol 39, 3110-3120 (2009)
16. Pawaria, S. &Binder, R. J. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat Commun 2, 521 (2011)
17. Yang, Y. et al.Heat shock protein gp96 is amaster chaperone for toll-like receptors and is important in the innate function of macrophages. Immunity 26, 215-226 (2007)
18. Warger, T. et al. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem 281, 22545-22553 (2006)
19. Binder, R. J. &Srivastava, P. K. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. P Natl Acad Sci USA 101, 6128-6133 (2004)
20. Randazzo, M., Terness, P., Opelz, G. &Kleist, C. Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited. Int. J. Cancer 130, 2219-2231 (2012)
21. Meng, S. D., Song, J., Rao, Z. H., Tien, P. &Gao, G. F. Three-step purification of gp96 from human liver tumor tissues suitable for isolation of gp96-bound peptides. J Immunol Methods 264, 29-35 (2002)
22. Yan, X. L. et al. Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activity. Cancer Immunol Immun 60, 1763-1774 (2011)
23. Manjili, M. H. et al. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 171, 4054-4061 (2003)
24. Jacob, J. et al. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 240, 96-106 (2006)
25. Gong, J. L. et al. A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use. J Immunol 184, 488-496 (2010)
26. Hobohm, U. Toward general prophylactic cancer vaccination. Bioessays 31, 1071-1079 (2009)
27. Eisenstein, M. Vaccines: Know your enemy. Nature 471, S8-S9 (2011)
28. Hao, J. et al. Inhibition of alpha interferon (IFN-Alpha)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-Alpha. J Virol 87, 137-147 (2013)
29. Livak, K. J. &Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25, 402-408 (2001)